 A disease re-evaluation will be scheduled every 8 weeks. Based on the Response Evaluation Criteria in Solid Tumors 1.1 RECIST1.1, response to treatment will be determined. Patients with stable disease SD, partial response PR or complete response CR may continue treatment until disease progression, unacceptable side effects, or patient refusalnon-compliance occurs. 